Shots:

• Zydus has received the US FDA’s approval to initiate clinical trials of Desidustat in CIA. The company has initiated two P-III studies of desidustat
• The P-III DREAM-ND (NCT04012957) study is being conducted in 588 CKD patients not-on-dialysis while the P-III DREAM-D is being conducted in 392 CKD patients on dialysis (NCT04215120)
• The therapy met its 1EPs in P-II study and demonstrated a good safety profile while P-I trials were earlier completed in Australia. Desidustat (PO) is a novel hypoxia-inducible factor prolyl hydroxylase inhibitor- currently undergoing P-III development for anemia in CKD patients- and P-II(b) studies for management of COVID-19 patients

  Ref: Zydus | Image: Twitter